WC
JANX icon

Wexford Capital’s Janux Therapeutics JANX Stock Holding History

Wexford Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,422
Closed -$34.8K – 451
2025
Q3 		$34.8K Sell
1,422
-5,119
-78% -$125K 0.01% 348
2025
Q2 		$151K Buy
+6,541
New +$172K 0.04% 191

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Wexford Capital's JANX Position: Q4 2025 in Review

Wexford Capital sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 1,422 shares — an estimated $34.8K sold.

Wexford Capital first reported a position in JANX in Q2 2025 and held it in 2 quarters. The position peaked at $151K in Q2 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Wexford Capital reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 1,422 Janux Therapeutics shares in Q4 2025, an estimated $34.8K.
  • Wexford Capital first reported a position in Janux Therapeutics in Q2 2025 and held it in 2 quarters.
  • Wexford Capital's Janux Therapeutics position peaked at $151K in Q2 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.